Hospital & Healthcare Services · Founded 2004 · www.medanta.org · BSE 543654 · NSE MEDANTA · ISIN INE474Q01031
No Notes Added Yet
Business
Global Health Ltd., operating under the brand name Medanta, is one of India's largest private multi-specialty tertiary and quaternary care providers. The company owns and operates a chain of hospitals that offer a wide range of medical services across various specialties including cardiology, cardiac surgery, oncology, neurosciences, liver and digestive diseases, orthopaedics, and kidney and urology. Its core business model revolves around providing comprehensive healthcare services to patients, encompassing inpatient, outpatient, diagnostic, and emergency care. The company generates revenue primarily through patient services, including consultations, surgeries, diagnostic tests, room charges, and pharmacy sales. It also caters to medical tourism patients seeking advanced medical care in India.
Revenue Mix
Global Health Ltd.'s revenue is primarily derived from its hospital services. While specific granular breakdowns may vary, the major components include:
Inpatient Services: Revenue from patients admitted for surgeries, treatments, and prolonged medical care. This typically forms the largest portion.
Outpatient Services: Revenue from consultations, day care procedures, and minor treatments.
Diagnostic Services: Revenue from a wide array of laboratory and imaging tests conducted within its facilities.
Pharmacy Sales: Revenue from medicines dispensed to both inpatient and outpatient customers.
Given its multi-specialty nature, revenue is distributed across various medical departments, with high-end specialties like cardiac sciences, oncology, and neurosciences often contributing significantly.
Industry
The Indian healthcare industry is characterized by a growing demand for quality healthcare services, driven by increasing population, rising disposable incomes, higher prevalence of chronic diseases, and evolving health insurance penetration. It is a mix of public and private providers, with private players like Global Health dominating the tertiary and quaternary care segment. Global Health is positioned as a premium provider of advanced, multi-specialty healthcare, particularly strong in the Delhi-NCR region (Gurugram) and expanding its presence in other key cities. It competes with other large corporate hospital chains such as Apollo Hospitals, Fortis Healthcare, Max Healthcare, and Narayana Hrudayalaya, differentiating itself through its specialist-led approach, state-of-the-art infrastructure, and reputation in complex procedures.
MOAT
Global Health's competitive advantages include:
Brand Reputation: The "Medanta" brand has established a strong reputation for clinical excellence, particularly in complex surgeries and super-specialties, attracting both domestic and international patients.
Talent Pool: Ability to attract and retain highly skilled and renowned doctors and medical professionals, which is crucial in tertiary care. The founder, Dr. Naresh Trehan, himself is a globally recognized cardiac surgeon.
Comprehensive Services: Offering a wide array of super-specialties under one roof, providing integrated care and making it a preferred choice for complex medical conditions.
Infrastructure & Technology: Investment in advanced medical technology and modern infrastructure supports complex procedures and enhances patient outcomes.
Scale and Network (Emerging): While not as vast as some older chains, its strategic expansion provides growing scale and regional dominance, particularly in specific markets.
Growth Drivers
Key factors that can drive Global Health's growth over the next 3-5 years include:
Increasing Healthcare Expenditure: Rising per capita healthcare spending and growing health insurance penetration in India.
Medical Tourism: Continued influx of international patients seeking high-quality, cost-effective advanced medical treatment.
Expansion of Capacity: Commissioning of new beds in existing facilities (e.g., Lucknow expansion) and strategic greenfield/brownfield expansion into new geographies.
Rising Burden of Non-Communicable Diseases (NCDs): Increasing prevalence of chronic diseases like cardiovascular ailments, cancer, and diabetes requiring advanced medical interventions.
Demand for Quality Private Healthcare: A significant portion of the Indian population continues to seek private healthcare services due to perceived quality and accessibility issues in the public sector.
Risks
Global Health faces several risks:
Regulatory & Pricing Risks: Government interventions in pricing for certain procedures or drugs, and evolving regulatory landscape for the healthcare sector.
Intense Competition: Highly competitive market with established domestic players and potential entry of new large hospital chains.
Talent Attrition: Dependence on key medical professionals and the risk of losing talent to competitors.
High Capital Expenditure: Healthcare is a capital-intensive business, requiring significant ongoing investment in infrastructure, technology, and maintenance.
Healthcare Inflation: Rising costs of medical supplies, equipment, and highly skilled labor.
Ethical & Reputational Risks: Any lapse in patient care or ethical standards can severely impact brand image and patient trust.
Management & Ownership
Global Health Ltd. is promoted and led by Dr. Naresh Trehan, a renowned cardiac surgeon, who plays a pivotal role in the company's strategic direction and clinical excellence. The company operates with a professional management team overseeing its day-to-day operations and growth initiatives. The ownership structure includes the promoter group, private equity investors (prior to IPO), and public shareholders following its listing. Dr. Trehan's vision and clinical leadership are central to the company's identity and service quality.
Outlook
Global Health Ltd. operates in a structurally growing Indian healthcare market, benefiting from increasing demand for specialized medical care, rising affluence, and expanding insurance coverage. Its established brand, clinical expertise, and strategic expansion plans position it well to capture this growth. The company's focus on high-acuity, super-specialty services provides higher revenue per bed and strong clinical outcomes. However, the sector is inherently capital-intensive, subject to regulatory scrutiny (especially on pricing), and faces intense competition for both patients and medical talent. Maintaining clinical excellence, managing operational costs, and navigating potential government policy changes will be crucial for sustained profitability and market leadership. The outlook is cautiously optimistic, balancing robust growth opportunities against operational complexities and competitive pressures inherent in the private healthcare sector.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 836 | 809 | 861 | 957 | 943 | 931 | 1031 | 1099 | 1121 | 1159 |
| Other Income | 18 | 27 | 22 | 18 | 16 | 23 | 20 | 20 | 22 | 37 |
| Total Income | 855 | 836 | 883 | 975 | 959 | 954 | 1051 | 1119 | 1143 | 1196 |
| Total Expenditure | 621 | 629 | 675 | 728 | 706 | 707 | 804 | 868 | 904 | 915 |
| Operating Profit | 234 | 207 | 208 | 247 | 254 | 248 | 247 | 251 | 239 | 281 |
| Interest | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 |
| Depreciation | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -50 | 20 | 16 | -37 | 0 |
| Profit Before Tax | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 |
| Provision for Tax | 49 | 16 | 37 | 50 | 46 | 32 | 49 | 41 | 25 | 46 |
| Profit After Tax | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 2 |
| Profit After Adjustments | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 144 |
| Adjusted Earnings Per Share | 4.6 | 4.7 | 4 | 4.9 | 5.3 | 3.8 | 5.9 | 5.9 | 3.5 | 5.4 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1194 | 1382 | 1277 | 1343 | 1441 | 1500 | 1447 | 2167 | 2710 | 3275 | 3692 | 4410 |
| Other Income | 36 | 45 | 67 | 49 | 65 | 44 | 31 | 39 | 49 | 75 | 105 | 99 |
| Total Income | 1230 | 1427 | 1344 | 1392 | 1506 | 1544 | 1478 | 2206 | 2759 | 3350 | 3797 | 4509 |
| Total Expenditure | 932 | 1081 | 1155 | 1218 | 1299 | 1309 | 1250 | 1709 | 2074 | 2466 | 2832 | 3491 |
| Operating Profit | 299 | 347 | 189 | 174 | 207 | 235 | 228 | 497 | 686 | 884 | 965 | 1018 |
| Interest | 9 | 14 | 23 | 28 | 21 | 57 | 73 | 86 | 86 | 84 | 74 | 80 |
| Depreciation | 64 | 70 | 81 | 86 | 91 | 115 | 123 | 130 | 150 | 173 | 194 | 223 |
| Exceptional Income / Expenses | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -50 | -1 |
| Profit Before Tax | 226 | 262 | 85 | 60 | 95 | 64 | 32 | 281 | 449 | 627 | 647 | 715 |
| Provision for Tax | 79 | 92 | 35 | 27 | 34 | 28 | 4 | 84 | 123 | 149 | 166 | 161 |
| Profit After Tax | 147 | 170 | 51 | 33 | 61 | 36 | 29 | 196 | 326 | 478 | 481 | 554 |
| Adjustments | 1 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Profit After Adjustments | 147 | 170 | 51 | 33 | 61 | 36 | 29 | 196 | 326 | 478 | 481 | 556 |
| Adjusted Earnings Per Share | 6.2 | 7.1 | 2.1 | 1.4 | 2.5 | 1.5 | 1.2 | 7.7 | 12.2 | 17.8 | 17.9 | 20.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 13% | 19% | 20% | 12% |
| Operating Profit CAGR | 9% | 25% | 33% | 12% |
| PAT CAGR | 1% | 35% | 68% | 13% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 4% | 26% | NA% | NA% |
| ROE Average | 15% | 16% | 13% | 11% |
| ROCE Average | 21% | 20% | 16% | 15% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 879 | 1057 | 1139 | 1217 | 1305 | 1350 | 1382 | 1616 | 2428 | 2906 | 3386 |
| Minority's Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 1 |
| Borrowings | 40 | 113 | 132 | 336 | 589 | 606 | 578 | 768 | 737 | 283 | 264 |
| Other Non-Current Liabilities | 78 | 76 | 109 | 97 | 87 | 403 | 722 | 819 | 352 | 436 | 463 |
| Total Current Liabilities | 214 | 238 | 272 | 334 | 279 | 358 | 405 | 419 | 573 | 618 | 619 |
| Total Liabilities | 1212 | 1485 | 1653 | 1984 | 2259 | 2716 | 3087 | 3622 | 4090 | 4243 | 4733 |
| Fixed Assets | 752 | 914 | 972 | 1089 | 1030 | 1703 | 1616 | 1776 | 2050 | 2236 | 2514 |
| Other Non-Current Assets | 50 | 62 | 53 | 423 | 739 | 534 | 969 | 1034 | 461 | 498 | 686 |
| Total Current Assets | 410 | 509 | 627 | 472 | 490 | 479 | 502 | 812 | 1579 | 1509 | 1533 |
| Total Assets | 1212 | 1485 | 1653 | 1984 | 2259 | 2716 | 3087 | 3622 | 4090 | 4243 | 4733 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 63 | 62 | 42 | 44 | 47 | 60 | 148 | 69 | 119 | 767 | 425 |
| Cash Flow from Operating Activities | 213 | 228 | 115 | 63 | 150 | 175 | 242 | 311 | 645 | 612 | 624 |
| Cash Flow from Investing Activities | -126 | -241 | -107 | -69 | -243 | -87 | -239 | -421 | -342 | -441 | -721 |
| Cash Flow from Financing Activities | -87 | -7 | -6 | 9 | 113 | -1 | -81 | 160 | 346 | -514 | -97 |
| Net Cash Inflow / Outflow | -0 | -20 | 2 | 3 | 19 | 87 | -78 | 50 | 648 | -343 | -194 |
| Closing Cash & Cash Equivalent | 62 | 43 | 44 | 47 | 66 | 148 | 69 | 119 | 767 | 425 | 230 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.18 | 7.06 | 2.09 | 1.36 | 2.48 | 1.47 | 1.16 | 7.75 | 12.16 | 17.81 | 17.92 |
| CEPS(Rs) | 8.82 | 9.98 | 5.41 | 4.92 | 6.18 | 6.14 | 6.13 | 12.87 | 17.75 | 24.24 | 25.13 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 |
| Book NAV/Share(Rs) | 35.31 | 41.99 | 43.89 | 45.79 | 49.62 | 51.42 | 53.14 | 63.6 | 90.35 | 108.05 | 126.07 |
| Core EBITDA Margin(%) | 21.99 | 21.81 | 9.57 | 9.33 | 9.87 | 12.77 | 13.61 | 21.14 | 23.48 | 24.7 | 23.3 |
| EBIT Margin(%) | 19.67 | 20 | 8.48 | 6.55 | 8.07 | 8.03 | 7.27 | 16.93 | 19.77 | 21.71 | 19.54 |
| Pre Tax Margin(%) | 18.92 | 18.97 | 6.68 | 4.44 | 6.61 | 4.26 | 2.24 | 12.95 | 16.58 | 19.15 | 17.53 |
| PAT Margin (%) | 12.28 | 12.32 | 3.96 | 2.45 | 4.23 | 2.42 | 1.99 | 9.05 | 12.03 | 14.6 | 13.04 |
| Cash Profit Margin (%) | 17.61 | 17.41 | 10.28 | 8.88 | 10.53 | 10.09 | 10.51 | 15.04 | 17.57 | 19.87 | 18.28 |
| ROA(%) | 12.1 | 12.62 | 3.23 | 1.81 | 2.88 | 1.46 | 0.99 | 5.85 | 8.46 | 11.47 | 10.72 |
| ROE(%) | 17.43 | 18.36 | 4.87 | 3.03 | 5.24 | 2.92 | 2.23 | 13.4 | 16.17 | 17.96 | 15.31 |
| ROCE(%) | 25.32 | 26.12 | 8.63 | 5.94 | 6.55 | 6.2 | 5.26 | 16.38 | 18.71 | 21.56 | 20.5 |
| Receivable days | 16.24 | 16.98 | 26.04 | 35.14 | 40.02 | 38.11 | 35.67 | 26.43 | 25.21 | 22.82 | 25.07 |
| Inventory Days | 7.73 | 7 | 7.02 | 6 | 5.83 | 7.52 | 9.87 | 7.84 | 7.66 | 7.09 | 6.62 |
| Payable days | 94.1 | 87.91 | 125.84 | 122.57 | 130.66 | 147.14 | 139.29 | 91.04 | 97.6 | 91.68 | 79.17 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43.28 | 74.33 | 66.85 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.82 | 12.25 | 9.5 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 |
| EV/Net Sales(x) | -0.15 | -0.12 | -0.16 | 0.18 | 0.3 | 0.3 | 0.3 | 0.17 | 5.05 | 10.62 | 8.5 |
| EV/Core EBITDA(x) | -0.59 | -0.47 | -1.09 | 1.4 | 2.05 | 1.93 | 1.92 | 0.76 | 19.95 | 39.37 | 32.52 |
| Net Sales Growth(%) | 0 | 15.72 | -7.59 | 5.17 | 7.29 | 4.11 | -3.58 | 49.81 | 25.03 | 20.86 | 12.74 |
| EBIT Growth(%) | 0 | 17.7 | -60.81 | -18.78 | 32.26 | 3.49 | -12.72 | 249.06 | 45.99 | 32.72 | 1.51 |
| PAT Growth(%) | 0 | 16.06 | -70.26 | -34.92 | 85.19 | -40.45 | -20.7 | 581.08 | 66.2 | 46.61 | 0.68 |
| EPS Growth(%) | 0 | 14.34 | -70.43 | -35.06 | 83.09 | -40.68 | -21.09 | 566.84 | 56.92 | 46.48 | 0.65 |
| Debt/Equity(x) | 0.06 | 0.13 | 0.17 | 0.37 | 0.49 | 0.48 | 0.48 | 0.52 | 0.35 | 0.14 | 0.1 |
| Current Ratio(x) | 1.92 | 2.14 | 2.31 | 1.41 | 1.76 | 1.34 | 1.24 | 1.94 | 2.76 | 2.44 | 2.48 |
| Quick Ratio(x) | 1.8 | 2.02 | 2.23 | 1.34 | 1.68 | 1.23 | 1.14 | 1.81 | 2.65 | 2.33 | 2.37 |
| Interest Cover(x) | 26.34 | 19.34 | 4.71 | 3.11 | 5.5 | 2.13 | 1.45 | 4.25 | 6.2 | 8.49 | 9.71 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.06 | 0.01 | 0.01 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.05 | 33.04 | 33.04 | 33.04 | 33.03 | 33.03 | 33.01 | 33.01 | 33.01 | 33.01 |
| FII | 11.36 | 12.09 | 12.94 | 12.2 | 12.47 | 11.76 | 11.54 | 11.4 | 10.53 | 10.15 |
| DII | 11.15 | 10.25 | 10.57 | 11.11 | 10.51 | 11.93 | 12.2 | 12.98 | 14 | 14.76 |
| Public | 44.44 | 44.61 | 43.44 | 43.65 | 43.98 | 43.28 | 43.25 | 42.61 | 42.46 | 42.08 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 |
| FII | 3.05 | 3.25 | 3.48 | 3.28 | 3.35 | 3.16 | 3.1 | 3.07 | 2.83 | 2.73 |
| DII | 2.99 | 2.75 | 2.84 | 2.98 | 2.82 | 3.2 | 3.28 | 3.49 | 3.76 | 3.97 |
| Public | 11.93 | 11.98 | 11.66 | 11.72 | 11.81 | 11.62 | 11.62 | 11.45 | 11.41 | 11.31 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26.84 | 26.85 | 26.85 | 26.85 | 26.86 | 26.86 | 26.88 | 26.88 | 26.88 | 26.88 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +13% | +19% | +20% | +12% |
| Operating Profit CAGR | +9% | +25% | +33% | +12% |
| PAT CAGR | +1% | +35% | +68% | +13% |
| Share Price CAGR | +4% | +26% | — | — |
| ROE Average | +15% | +16% | +13% | +11% |
| ROCE Average | +21% | +20% | +16% | +15% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.05 | 33.04 | 33.04 | 33.04 | 33.03 | 33.03 | 33.01 | 33.01 | 33.01 | 33.01 |
| FII | 11.36 | 12.09 | 12.94 | 12.2 | 12.47 | 11.76 | 11.54 | 11.4 | 10.53 | 10.15 |
| DII | 11.15 | 10.25 | 10.57 | 11.11 | 10.51 | 11.93 | 12.2 | 12.98 | 14 | 14.76 |
| Public | 66.95 | 66.96 | 66.96 | 66.96 | 66.97 | 66.97 | 66.99 | 66.99 | 66.99 | 66.99 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 |
| FII | 3.05 | 3.25 | 3.48 | 3.28 | 3.35 | 3.16 | 3.1 | 3.07 | 2.83 | 2.73 |
| DII | 2.99 | 2.75 | 2.84 | 2.98 | 2.82 | 3.2 | 3.28 | 3.49 | 3.76 | 3.97 |
| Public | 17.97 | 17.98 | 17.98 | 17.98 | 17.99 | 17.99 | 18 | 18.01 | 18.01 | 18.01 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26.84 | 26.85 | 26.85 | 26.85 | 26.86 | 26.86 | 26.88 | 26.88 | 26.88 | 26.88 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.